Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

Fabio Massimo PerrottaFulvia CeccarelliCristiana BarbatiTania ColasantiAntonia De SocioSilvia ScriffignanoCristiano Alessandri Ennio Lubrano

Published in: Journal of immunology research (2018)

The results of our study suggest a possible role of sclerostin in the identification of AS patients. Further studies are needed to prove the role of sclerostin as a disease activity biomarker and progression of disease in AS.

Keyphrases

ankylosing spondylitis
disease activity
rheumatoid arthritis
systemic lupus erythematosus
end stage renal disease
rheumatoid arthritis patients
chronic kidney disease
newly diagnosed
juvenile idiopathic arthritis
ejection fraction
peritoneal dialysis
patient reported outcomes
case control